Rapivab FDA Approval History
FDA Approved: Yes (First approved December 19, 2014)
Brand name: Rapivab
Generic name: peramivir
Dosage form: Injection
Company: BioCryst Pharmaceuticals, Inc.
Treatment for: Influenza
Rapivab (peramivir) is an influenza virus neuraminidase inhibitor indicated for the treatment of acute uncomplicated influenza.
Development timeline for Rapivab
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.